Unfortunately, I don't believe this is at all true. MSB rose and fell on poor management. PAR have had terrible management. You could argue these drugs have a lot of great data to get approved. Management have done a lot to stifle their progression.
in most instances, the potential of a drug is only appreciated due to KMP.
RAC Price at posting:
$1.69 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)